FLAURA2：奥希替尼联合铂类/培美曲塞一线治疗 EGFR 突变晚期 NSCLC

类型: 论文 发表日期: 2023-11-23 入库日期: 2026-05-21 来源: NEJM / FDA 标签: EGFR L858R, 奥希替尼, 培美曲塞, 卡铂, FLAURA2, 一线治疗

Citation

Planchard D, Janne PA, Cheng Y, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. New England Journal of Medicine. 2023. DOI: 10.1056/NEJMoa2306434

FDA approval note: FDA approves osimertinib with chemotherapy for EGFR-mutated NSCLC

Why this is in CCL

Mom has EGFR exon 21 L858R metastatic NSCLC and has been treated with osimertinib plus platinum/pemetrexed-style chemotherapy. This is the central phase III evidence base for that strategy in treatment-naive locally advanced/metastatic EGFR exon 19 deletion or L858R NSCLC.

Key takeaways

• Population: advanced EGFR-mutated NSCLC with exon 19 deletion or L858R.
• Intervention: osimertinib plus pemetrexed and cisplatin/carboplatin.
• Comparator: osimertinib alone.
• FDA summary reports PFS improvement: median PFS 25.5 months vs 16.7 months; HR 0.62.
• Toxicities are more hematologic with chemo: leukopenia, thrombocytopenia, neutropenia, lymphopenia are specifically highlighted by FDA.

Practical relevance

• Supports the biological and clinical logic of adding platinum/pemetrexed to osimertinib in higher-risk EGFR-mutated disease.
• Mom’s chronic lymphopenia and blood-count suppression should be interpreted with awareness that FLAURA2-style treatment increases marrow toxicity.
• Useful when discussing whether current chemo intensity, maintenance, re-challenge, or dose/timing adjustments are consistent with evidence.